The latest News Headlines from the Scientific, Research and HighTech world

Články z PhysOrgGene testing identifies lung cancer patients who benefit from ALK-inhibitor drug

13. 1 2010 (07:56)

Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.